Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.
| Health Care Equipment & Supplies Industry | Healthcare Sector | James Patrick Mackin CEO | XSTU Exchange | US2289031005 ISIN |
| US Country | 1,600 Employees | 12 Mar 2014 Last Dividend | 28 Dec 2000 Last Split | - IPO Date |
Artivion, Inc., initially known as CryoLife, Inc., before its name change in January 2022, is a prominent entity in the medical devices and implantable human tissues sector, with operations extending globally. Founded in 1984 and based in Kennesaw, Georgia, the company is adept at manufacturing, processing, and distributing a wide array of medical devices. These products are designed for use in various medical procedures, including cardiac, vascular, neurologic, and pulmonary operations. Artivion, Inc. caters to a diverse clientele, including physicians, hospitals, and other healthcare facilities, with its offerings significantly influencing the practices of cardiac, vascular, thoracic, and general surgeons across the world.